Advertisement

Hikma Pharmaceuticals upgrades 2013 revenue outlook

Shares in Hikma Pharmaceuticals rose Thursday after the company upgraded its 2013 revenue growth forecast following a "strong start to the year".

Shares in Hikma Pharmaceuticals rose Thursday after the company upgraded its 2013 revenue growth forecast following a "strong start to the year".

The group expects revenue to rise 13% this year, up from its previous guidance of 10%, driven by the performance of Branded and Injectables and Generics businesses in the year-to-date.

Advertisement - Article continues below

The Branded and Injectables unit is on track to meet the firm's full-year guidance while the Generics arm is continuing to benefit from its doxycycline product which is delivering revenue ahead of forecasts.

"We have made a very good start to 2013 across all of our businesses and I am pleased to be able to raise our group guidance for the full year," said Chief Executive Officer Said Darwazah.

The company's branded business was boosted by the introduction of new products and enhancements in sales and marketing activities. The unit has experienced improvement in markets including Algeria, Egypt and Saudi Arabia.

In January, Hikma completed the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries which has since been fully integrated.

Branded revenue is expected to increase 11% in 2013, with a slight improvement in adjusted operating margin.

The Injectables division has been performing well in the US, supported by new product launches, price improvements and our continued focus on operational efficiencies.

Full-year guidance for the Generics business is for revenue of $150m and operating margin in the low teens.

"Overall, our diversified business model is positioning the group to deliver another strong year in 2013," Arabia said.

Shares climbed 2.32% to 1,014p at 12:43 Thursday.

RD

Advertisement
Advertisement

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

OBR: UK house prices could fall by 12% next year
House prices

OBR: UK house prices could fall by 12% next year

The Office for Budget Responsibility says UK house prices could fall by as much as 12% next year. John Stepek looks at how likely that is.
14 Jul 2020
Three ideas for Lloyds Bank's new boss
UK stockmarkets

Three ideas for Lloyds Bank's new boss

The Black Horse needs whipping into shape. A change at the top provides a great opportunity, says Matthew Lynn.
12 Jul 2020
We’re spending more than at any time since World War II – how will we pay it back?
UK Economy

We’re spending more than at any time since World War II – how will we pay it back?

With the UK spending vast sums on stimulus measures, this year’s budget deficit will be greater than at any time since World War II. The big question,…
14 Jul 2020